ONCOassist

ONCOassist A revolutionary app designed by oncology professionals for oncology professionals. The go-to app for all oncology professionals.

It gives them comfort where they can access relevant, up to date tools and content at their fingertips. It is the only mobile-first platform that saves time and improves the quality of patient care for frustrated and under pressure oncology HCPs. With the advent of genomic sequencing, combined with an aging population, and new therapies. The decision-making process for oncology HCP's is becoming increasingly complex. Unfortunately, they have no easy access to the tools and information they need to make an informed decision quickly. This means they use multiple different software and tools to aid their decisions, many of which are not safe and validated. This wastes time & reduces the quality of patient care. We focus on making ONCOassist easily accessible to all oncology HCP’s by being available across multiple devices(iOS, Android, and Desktop) and ensuring safety through CE and FDA compliance. Such is the need for ONCOassist our community of users are actively engaging with us to help define our future tools based on their burning needs. ONCOassist is improving the delivery of cancer care globally and helping us to reach our goal of leveling the standard of care worldwide.

13/02/2026

👉️ Take the Small Cell Lung Cancer ONCO-IQ quiz - https://bit.ly/SCLC-ONCO-IQ

This peer-reviewed ONCO-IQ quiz is designed for oncology professionals, a fast, high-yield knowledge check you can complete in minutes.

✅️ Recognise staging distinctions and first-line systemic therapy choices in SCLC.
✅️ Understand the role of immunotherapy and key supportive care strategies in SCLC management.

12/02/2026

🔬Access German Hodgkin Lumphoma Risk Groups in

Try the tool from the link in bio

🚨 Latest Approval Update! 🔷 U.S. FDA approves Optune Pax® for first-line treatment of locally advanced pancreatic canc...
12/02/2026

🚨 Latest Approval Update!

🔷 U.S. FDA approves Optune Pax® for first-line treatment of locally advanced pancreatic cancer in combination with gemcitabine and nab-paclitaxel, the first new FDA-approved therapy in nearly 30 years for this setting.

🔷 In the Phase 3 PANOVA-3 study, Optune Pax® + gem/nab-pac improved median overall survival (OS) to 16.2 months (95% CI 15.0–18.0) vs 14.2 months (95% CI 12.8–15.4) (HR 0.82; p=0.039), with delayed pain progression and improved distant PFS.

🔷 Introduces Tumor Treating Fields (TTFields) therapy, a novel, noninvasive, biophysical treatment modality.

🔗 Read more: https://bit.ly/ONCOnews12Feb-02

🚨 Latest Approval Update! 🔷 Agilent’s PD-L1 IHC 22C3 pharmDx receives FDA approval for use in epithelial ovarian, fall...
12/02/2026

🚨 Latest Approval Update!

🔷 Agilent’s PD-L1 IHC 22C3 pharmDx receives FDA approval for use in epithelial ovarian, fallopian tube, and primary peritoneal carcinoma (EOC).

🔷 Agilent’s PD-L1 IHC 22C3 pharmDx is a pathology test (immunohistochemistry assay) used to measure PD-L1 protein expression on tumor cells and immune cells in a tissue sample.

🔷 This approval supports biomarker-driven treatment selection and expands access to precision immunotherapy in advanced gynecologic cancers.

🔗 Read more: https://bit.ly/ONCOnews12Feb-01

🚨 Latest Approval Update! 🔷 The FDA has approved pembrolizumab (Keytruda®, Merck) and pembrolizumab + berahyaluronidas...
11/02/2026

🚨 Latest Approval Update!

🔷 The FDA has approved pembrolizumab (Keytruda®, Merck) and pembrolizumab + berahyaluronidase alfa-pmph (Keytruda Qlex®, Merck) in combination with paclitaxel (± bevacizumab) for adults with PD-L1 (CPS ≥1) platinum-resistant epithelial ovarian, fallopian tube, or primary peritoneal carcinoma after 1–2 prior systemic regimens.

🔷 The approval is based on KEYNOTE-B96, which demonstrated improvements in progression-free survival (PFS) and overall survival (OS), introducing an immunotherapy-based combination strategy in platinum-resistant disease.

🔗 Read more: https://bit.ly/ONCOnews11Feb-01

🚨 Latest Update! 🔷 Median Technologies has received FDA 510(k) clearance for eyonis® LCS (Lung Cancer Screening), the ...
10/02/2026

🚨 Latest Update!

🔷 Median Technologies has received FDA 510(k) clearance for eyonis® LCS (Lung Cancer Screening), the first AI-based medical device cleared for lung cancer detection and diagnosis in a screening setting, supporting earlier and more accurate identification of disease.

🔷 Designed for low-dose Computed Tomography (CT) screening, eyonis® LCS enables earlier lung cancer detection through pulmonary nodule characterization, demonstrating 93.3% sensitivity, 92.4% specificity, and a 99.9% negative predictive value.

🔗 Read more: https://bit.ly/ONCOnews10Feb-02

🚨 Latest 3 Trial Update! 🔷 Nuvation Bio has initiated the pivotal, global Phase 3 SIGMA (G203) trial evaluating safusi...
10/02/2026

🚨 Latest 3 Trial Update!

🔷 Nuvation Bio has initiated the pivotal, global Phase 3 SIGMA (G203) trial evaluating safusidenib, an oral, brain-penetrant IDH1 inhibitor, in patients with IDH1-mutant glioma, aiming to address a high unmet need in this molecularly defined population.

🔷 The randomized study is designed to assess efficacy and safety versus placebo, with progression-free survival (PFS) as the primary endpoint.

🔗 Read more: https://bit.ly/ONCOnews10Feb-01

09/02/2026

Comment the right answer 👇

Participate in this week’s Early Breast Cancer quiz 🔗link in bio🔗

Explore early breast cancer and other oncology quizzes across multiple indications, now live on



[Oncology Quiz, ONCOassist, Oncology Tool]

🚨 Latest Approval Update! 🔷 The FDA has approved a label update for Kite Pharma’s Yescarta® (axicabtagene ciloleucel),...
09/02/2026

🚨 Latest Approval Update!

🔷 The FDA has approved a label update for Kite Pharma’s Yescarta® (axicabtagene ciloleucel), expanding its indication to include adults with relapsed or refractory primary central nervous system (CNS) lymphoma.

🔷 This update reflects growing evidence supporting CAR T-cell therapy in a high-risk population with limited treatment options, marking a meaningful step forward in CNS lymphoma care.

🔗 Read more: https://bit.ly/ONCOnews09Feb-01

06/02/2026

👉Take the Early Breast Cancer ONCO-IQ quiz now - https://bit.ly/EBC_ONCO_IQ_FB

This peer-reviewed ONCO-IQ quiz is designed for oncology professionals, a fast, high-yield knowledge check you can complete in minutes.

✅Apply evidence from landmark neoadjuvant and adjuvant trials to early breast cancer management
✅Interpret genomic risk stratification tools to guide adjuvant therapy decisions
✅Identify high-risk features and select appropriate recurrence-risk reduction strategies in early breast cancer

Address

3rd Floor, 41/42, High Street
Killarney
V93T8K7

Website

Alerts

Be the first to know and let us send you an email when ONCOassist posts news and promotions. Your email address will not be used for any other purpose, and you can unsubscribe at any time.

Contact The Practice

Send a message to ONCOassist:

Shortcuts

Share

Share on Facebook Share on Twitter Share on LinkedIn
Share on Pinterest Share on Reddit Share via Email
Share on WhatsApp Share on Instagram Share on Telegram

Category